We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest close session, Eli Lilly (LLY - Free Report) was down 1.89% at $905.03. This change lagged the S&P 500's 0.8% gain on the day. Elsewhere, the Dow lost 0.15%, while the tech-heavy Nasdaq added 1.6%.
The drugmaker's shares have seen a decrease of 0.84% over the last month, not keeping up with the Medical sector's loss of 0.77% and the S&P 500's gain of 5.15%.
The investment community will be closely monitoring the performance of Eli Lilly in its forthcoming earnings report. The company is scheduled to release its earnings on April 30, 2026. On that day, Eli Lilly is projected to report earnings of $7.52 per share, which would represent year-over-year growth of 125.15%. In the meantime, our current consensus estimate forecasts the revenue to be $17.62 billion, indicating a 38.45% growth compared to the corresponding quarter of the prior year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $34.32 per share and a revenue of $82.06 billion, representing changes of +41.76% and +25.9%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Eli Lilly. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.15% lower. Eli Lilly currently has a Zacks Rank of #3 (Hold).
Looking at valuation, Eli Lilly is presently trading at a Forward P/E ratio of 26.88. This represents a premium compared to its industry average Forward P/E of 14.63.
We can additionally observe that LLY currently boasts a PEG ratio of 1.08. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.33 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 171, which puts it in the bottom 30% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
In the latest close session, Eli Lilly (LLY - Free Report) was down 1.89% at $905.03. This change lagged the S&P 500's 0.8% gain on the day. Elsewhere, the Dow lost 0.15%, while the tech-heavy Nasdaq added 1.6%.
The drugmaker's shares have seen a decrease of 0.84% over the last month, not keeping up with the Medical sector's loss of 0.77% and the S&P 500's gain of 5.15%.
The investment community will be closely monitoring the performance of Eli Lilly in its forthcoming earnings report. The company is scheduled to release its earnings on April 30, 2026. On that day, Eli Lilly is projected to report earnings of $7.52 per share, which would represent year-over-year growth of 125.15%. In the meantime, our current consensus estimate forecasts the revenue to be $17.62 billion, indicating a 38.45% growth compared to the corresponding quarter of the prior year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $34.32 per share and a revenue of $82.06 billion, representing changes of +41.76% and +25.9%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Eli Lilly. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.15% lower. Eli Lilly currently has a Zacks Rank of #3 (Hold).
Looking at valuation, Eli Lilly is presently trading at a Forward P/E ratio of 26.88. This represents a premium compared to its industry average Forward P/E of 14.63.
We can additionally observe that LLY currently boasts a PEG ratio of 1.08. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.33 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 171, which puts it in the bottom 30% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.